The enhanced willingness of those offered the option of inhaled insulin treatment to change to a more appropriate therapy increases the potential for achieving improved glycemic control and reducing complications, associated morbidity, premature mortality, and increased cost of diabetes. This evidence concerns the gene INS and diabetes mellitus.